SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers

Shun Matsuura1,2, Tomoaki Kahyo1, Kazuya Shinmura1, Moriya Iwaizumi1, Hidetaka Yamada1, Kazuhito Funai3, Jun Kobayashi4, Masayuki Tanahashi5, Hiroshi Niwa6, Hiroshi Ogawa6, Takashi Takahashi7, Naoki Inui2, Takaumi Suda2, Kingo Chida2, Yoshinori Watanabe8 & Haruhiko Sugimura1

1Department of Tumor Pathology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan, 2Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan, 3First Department of Surgery, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan, 4Thoracic Surgery, Shimada Municipal Hospital, 1200-5 Noda, Shimada, Shizuoka, 427-8502, Japan, 5Division of Thoracic Surgery, Respiratory Disease Center, 6Division of Pathology, Seirei Mikatahara General Hospital, 3453 Mikatahara, Kita Ward, Hamamatsu, Shizuoka, 433-8558, Japan, 7Department of Molecular Carcinogenesis, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showaku, Nagoya, Aichi, 466-8550, Japan, 8Laboratory of Chromosome Dynamics, Institute of Molecular and Cellular Biosciences, University of Tokyo, Yayoi, Tokyo, 113-0032, Japan.

Mitosis is the most conspicuous cell cycle phase and Shugoshin-like 1 (SGOL1) is a key protein in protecting sister chromatids from precocious separation during mitosis. We studied the role of SGOL1 and its splice variants in non-small cell lung cancer (NSCLC) using 82 frozen NSCLC tissue samples. SGOL1-B expression was prevalent in smokers, in cases with a wild-type (WT) EGFR status, and in cases with the focal copy number amplification of genes that are known to be important for defining the biological behaviors of NSCLC. The overexpression of SGOL1-B1 in an NSCLC cell line induced aberrant chromosome missegregation, precociously separated chromatids, and delayed mitotic progression. A higher level of SGOL1-B mRNA was related to taxane resistance, while the forced downregulation of SGOL1-B increased the sensitivity to taxane. These results suggest that the expression of SGOL1-B causes abnormal mitosis and taxane resistance in NSCLC cells.
Results

Increased SGOL1-B expression in NSCLC. To investigate the status of SGOL1 expression in NSCLC tissues, the mRNA level of SGOL1 was quantified using real-time RT-PCR with primers covering the SGOL1-A, -B, and -C splicing variants (Figures 1a and b) in 82 pairs of primary NSCLC and matched normal tissues located adjacent to the carcinoma. Increased SGOL1 expression (T > N) was observed in 62 (73.6%) of the 82 NSCLCs (Figure 1c); moreover, a significant difference was detected in the mRNA expression level of SGOL1 between cancerous and non-cancerous tissue using a statistical analysis (P < 0.0001 according to a Wilcoxon matched pairs test). This result suggests that SGOL1 expression is upregulated in NSCLC.

Since several splicing variants of SGOL1 exist (Figure 1a), we next examined whether the mRNA expression of each SGOL1 variant was upregulated in the 82 NSCLCs. We compared the expression level of each SGOL1 variant in matched pairs of cancerous and non-cancerous tissues. A paired comparison in all cases revealed a statistically significant increase in the expression of SGOL1-B, but not of SGOL1-A or SGOL1-C, in the cancerous tissue, compared with the non-cancerous tissues (Figure 1d, P = 0.047). Very interestingly, all the cancers expressing SGOL1-B (n = 24) showed increased expression levels in the cancerous tissue, compared with the non-cancerous tissue (cancer tissue-specific expression). We analyzed the contributions of other SGOL1 isoforms to the phenotype exerted by SGOL1-B1 expression. In SGOL1-B expressing cases, the ratio SGOL1-A/SGOL1-B is larger than 1.0 while SGOL1-C/SGOL1-B is lower than 1.0 (Supplementary Table S1 online). These results suggest that SGOL1-B has an important role in the carcinogenesis of NSCLC; therefore, we focused on SGOL1-B in the subsequent studies.

Association of SGOL1-B expression with EGFR status and focal copy number amplifications in NSCLC. Next, we investigated whether the levels of SGOL1-B mRNA expression were associated with the clinicopathological features in NSCLC patients (Table 1). The frequencies of patients with smoking history and WT EGFR were statistically higher in the group with SGOL1-B-positive cancer than in the group with SGOL1-B-negative cancer (P = 0.029 and P = 0.017, respectively). No associations were found between the clinicopathological factors of sex, onset age, tumor pathology, or tumor stage and the status of SGOL1-B mRNA expression in the cancerous tissue.

Then, we hypothesized that SGOL1-B-positive lung cancers may have more frequent and extensive genomic alterations. To assess the association between SGOL1-B expression and genetic alterations, we selected five DNA targets commonly amplified in lung cancer, i.e., 8p12 (FGFR1), 3q26.3-q27 (SOX2 and PIK3CA), 7q31.1 (MET), and 7p12 (EGFR), and evaluated their gene copy changes using FISH in a tissue microarray11-15. A specific relationship was not observed between SGOL1-B expression and focal copy number amplification at a particular locus, but focal copy number amplifications at one of these loci were identified in 18 of the 58 (31.0%) patients with SGOL1-B negative cancer and in 13 of the 24 (54.2%) patients with SGOL1-B positive cancer (P = 0.049, Table 1). The mechanisms of these focal copy number amplifications are not known, but SGOL1-B-positive cancer represents a subset of lung cancers with focal copy number amplifications.

SGOL1-B1 is localized at centromeres, and SGOL1-B1 overexpression exhibits aberrant chromosome-alignment during mitosis in lung cancer cells. To characterize the effect of SGOL1-B expression in NSCLC, the lung adenocarcinoma cell line ACC-LC-176 was transfected with an expression vector for MYC-tagged SGOL1-B1. The overexpression of MYC-SGOL1-B1 was confirmed in ACC-LC-176 cells using a western blot analysis (Figure 2a). An immunofluorescence analysis revealed that SGOL1-B1 was localized in the nucleus during interphase and mitosis (Figure 2b). To further investigate the specific localization of SGOL1-B1, we performed a co-immunofluorescence study for the centromere and MYC-SGOL1-B1. MYC-SGOL1-B1 was clearly localized at the centromere in SGOL1-B1-overexpressing cells (Figure 2c). Furthermore, when we focused on the chromosome positioning morphology during mitosis, chromosome missegregation in pro-metaphase was more frequently observed in SGOL1-B1-overexpressing cells than in empty-vector transfected cells (66.7% vs. 6.8%) (Figure 2c). These results suggested that SGOL1-B1 overexpression is associated with mitotic abnormalities. Furthermore, we tested to see if the overexpression of SGOL1-A1 rescued the phenotype induced by the overexpression of SGOL1-B1. The chromosome missegregation induced by SGOL1-B1 was partially dismissed in the presence of SGOL1-A1 (Figure 2d).

Since multiple spindle poles have been reported to be common in mitotic SGOL1-knockdown cells (1), we examined the cells for the presence of centrosome amplification (an extra centrosome; more than 3 centrosomes). Centrosome amplification was observed more frequently in ACC-LC-176 cells expressing SGOL1-B1 than in the vector control cells (Figure 2e). All these results suggested that SGOL1-B1 is localized at the centromere and that the overexpression of SGOL1-B1 exhibits aberrant chromosome-alignment in lung cancer cells.

Association between SGOL1-B expression and the response to taxanes in NSCLC cells with WT EGFR. Despite the recent development of various new drugs targeting specific molecules, anti-mitotic drug taxanes are still the mainstay of treatment for advanced NSCLC with WT EGFR. Since an association between the WT EGFR status and SGOL1-B expression was observed in Table 1, we examined whether the expression status of SGOL1-B was associated with the sensitivity to taxanes, such as docetaxel or paclitaxel. First, the mRNA expression levels of SGOL1-B were determined in three NSCLC cell lines with WT EGFR and a NSCLC cell line with EGFR mutation. The SGOL1-B expression levels were low in PC-3 and A549 cells.
Figure 1 | Expression of SGOL1 variants in NSCLC tissue. (a) Scheme of SGOL1 transcript variants. The filled boxes represent exons (exons 1–9). The coding region is indicated in gray, and the non-coding region is indicated in black. The number at the right indicates the length of the protein coding sequence. (b) Amplified products of various SGOL1 transcripts using quantitative real-time RT-PCR. Specific primers for each SGOL1 variant (A, B, C, and P) or primers targeting variants A, B, and C were used for the PCR. After the quantitative real-time RT-PCR reaction using a LightCycler instrument, the PCR products were electrophoresed and stained with ethidium bromide in an agarose gel to confirm the production of objective products. The number and “C” below the panel indicate the case number and negative control, respectively. (c) Measurement of the SGOL1 mRNA expression levels in 82 paired human NSCLC and normal lung tissues using quantitative real-time RT-PCR. Expression of SGOL1 transcripts containing variants A, B, and C. After normalizing the expression levels of SGOL1 to those of GAPDH, the T/N values were calculated by dividing the amount of normalized transcripts in the tumor tissue by the amount in the corresponding normal lung tissue. Cases were grouped into two categories according to their T/N value: SGOL1 downregulation (T/N < 1) and SGOL1 upregulation (T/N > 1). Differences between the normalized SGOL1 mRNA level in the tumor tissue and the corresponding normal tissue were statistically analyzed using the Wilcoxon matched pairs test, and the $P$-value was less than 0.0001. Data were calculated from triplicate measurements. (d) Paired comparison of mRNA expression from normal and tumor samples in each SGOL1 splice variant in all cases. *$P$ < 0.05 (Student $t$-test).
To exclude the possibility that differences other than the SGOL1-B expression level between A549 and ACC-LC-176 cells affect the taxane response, we examined the effect of SGOL1-B overexpression on taxane resistance in A549 cells. The ectopic overexpression of SGOL1-B1 enhanced the cellular viability after treatment with docetaxel or paclitaxel in A549 cells (Figure 5a). We next performed time-lapse microscopy to examine A549 cells expressing SGOL1-B1 and measured the rate of each type of cell death caused by treatment with 1,000 nM of docetaxel. Strikingly, the proportion of cells exhibiting “death in mitosis” was markedly increased by SGOL1-B1 overexpression (2.6% in control cells vs. 25.0% in cells overexpressing SGOL1-B1) (Figure 5b and Supplementary Movie 6 online). Next, we performed the knockdown of SGOL1-B in ACC-LC-176 cells to examine the role of abundant endogenous SGOL1-B. Western blotting confirmed the downregulation of SGOL1-B expression (Figure 5c). The decrease in the SGOL1-B expression level led to an increased sensitivity of ACC-LC-176 cells to docetaxel and paclitaxel (Figure 5d). Moreover, the proportion of cells exhibiting “death in interphase” after treatment with 1,000 nM of docetaxel was markedly increased by SGOL1-B1 knockdown (Figure 5e and Supplementary Movie 7 online). A similar result was obtained in H1299 cells (Supplementary Figure S1 online). These results suggest that the SGOL1-B expression level defines taxane resistance in NSCLC with WT EGFR.

**Discussion**

The key findings of our study are that SGOL1 expression is upregulated in NSCLC and that the upregulation of SGOL1-B is associated with ominous clinical feature such as having WT EGFR and focal copy number amplification. SGOL1-B1 overexpression induced aberrant chromosome alignment during mitosis, the precocious separation of sister chromatids, and a delay in the onset of anaphase in lung cancer cells. Furthermore, taxane-resistance in lung cancer cells was shown to be associated with an elevated expression of SGOL1-B and mitotic arrest.

We have shown that SGOL1 was predominantly expressed in the tumorous regions of lung tissues, relative to normal tissues contrasting to the case of colon cancer, in which SGOL1 is downregulated, compared with its expression in normal tissues. It is not surprising because gene expression patterns often differ among cancers in different organs, but we do not know the implication of this difference in SGOL1 expression profile at this moment.

Genomic amplifications have long been recognized in lung cancer. Genomic profiling studies of NSCLC, using FISH, have revealed focal copy number alterations of the chromosomal area of known oncogenes, such as FGFR1 (8p12), SOX2 (3q26.3-q27), PIK3CA (3q26.3), MET (7q31.2), and EGFR (7p12.2). In our study, the profile of these genetic alterations according to different histological types of lung cancer was consistent with that of previous studies (Supplementary Table S2 online). The expression of SGOL1-B was increased specifically in lung cancer with focal copy number amplifications. Our *in vitro* studies also suggest that the overexpression of SGOL1-B in lung cancer may cause genomic instability (Supplementary Table S3 online). Thus, we hypothesized that SGOL1-B-positive cancer could be predisposed to genomic instability. The reasons for the amplifications of focal genomic areas are not known and have been investigated.
Figure 2 | Centromeric localization and aberrant chromosome alignment during mitosis in lung cancer cells expressing SGOL1-B1. (a) Ectopic expression of SGOL1-B1 in the human NSCLC cell line ACC-LC-176. The cells were transfected with the expression vector for MYC-SGOL1-B1, and the cellular extracts were subjected to a western blot analysis. Cropped images are shown and original whole gels and cropped lines are in Supplementary Figure S2 online. (b) Localization of SGOL1-B1 during the cell cycle. Cells at interphase (middle panels) and prophase-metaphase (lower panels) are shown using staining for MYC-SGOL1-B1 (red), β-tubulin (green) and DNA (blue). (c) Centromeric localization of SGOL1-B1. ACC-LC-176 cells were transfected with an empty vector or a MYC-SGOL1-B1 expression vector, and after synchronization to metaphase using nocodazole, the cells were stained with an anti-MYC antibody (red), anti-centromere antibody (green) and DAPI (blue). The inset shows a magnified image of the centromere. The mitotic cell expressing MYC-SGOL1-B1 (lower panels) shows chromosome missegregation. An attached graph shows percentage of cells exhibiting chromosome missegregation. The results are presented as (n = 50) from three independent experiments. (d) Rescue of SGOL1-B1-derived missegregation phenotype by the overexpression of SGOL1-A1 in NSCLC cells. ACC-LC-176 cells were transfected with GFP-empty or GFP-SGOL1-A1 vector together with the MYC-SGOL1-B1 expression vector. At 20 h post-transfection, the cells were synchronized to metaphase with nocodazole, fixed, and stained with an anti-MYC antibody (red) and DAPI (blue). Chromosome missegregation is shown in the upper panels, while the chromosomes were properly segregated in the lower panels. Scale bar = 5 μm. Statistical analysis of misaligned chromosomes in experiment. Results are presented (n = 50) from three independent experiments. (e) Centrosome amplification detected in ACC-LC-176 cells expressing SGOL1-B1. The cells were transfected with an empty vector or a MYC-SGOL1-B1 expression vector, and at 48 h post-transfection, the cells were stained with an anti-MYC antibody (green), anti-γ-tubulin (red), and DAPI (blue). Scale bar = 5 μm. An attached graph shows percentage of cells exhibiting centrosome amplification. Results are presented (n = 200) from three independent experiments.
Figure 3 | Cohesion defects between sister chromatids and delayed mitotic progression in lung cancer cells expressing SGOL1-B1. (a) Representative images of chromosome spread exhibiting cohesion defects. The NSCLC cell line ACC-LC-176 was transfected with GFP-H2B expression vector together with the MYC-SGOL1-B1 expression vector, SGOL1 shRNA vector, or control vector. The cells were then treated with nocodazole to arrest the cell cycle during mitosis, and the chromosomes were spread, stained with DAPI, and classified into the following three patterns: (I) tightly connected pattern, normal cohesive chromatids or only a very few pairs of separated sister chromatids; (II) abnormally spaced pattern, separated chromatids have remained in close proximity to the pair partner (several chromatid pairs remain cohesive); and (III) complete separation pattern, severely separated chromatids (the pair partner is often hard to identify because it is located some distance away). (b) Percentage of cells with cohesion defects between sister chromatids in experiment (a). *P < 0.05 (Fisher exact test). (c) Detection of delayed mitotic progression in ACC-LC-176 cells transfected with vectors as described in (a) using time-lapse analysis. The mitotic progression time was defined as the elapsed time from NEBD to anaphase onset. Images were acquired every 5 min. The elapsed time in minutes is shown at the upper right of each panel. Scale bar = 10 μm. (d) Quantitation of the mitotic progression time in experiment (c). Each symbol in the scatter plot represents a single cell. The solid horizontal bars represent the median values. *P < 0.0005 [Mann-Whitney U-test]. The numbers of examined cells are indicated in parentheses.
sparsely addressed in previous literature. Our observation may imply that a guardian of mitosis control and its aberrant spliced product may bring about global instability in the genome, causing the amplification of particularly sensitive regions of the chromosomes. Our present study revealed a new and important role of SGOL1-B in lung cancer progression. The overexpression of SGOL1-B has been associated with centrosome amplification. Multiple spindle poles have been reported to be common in mitotic SGOL1-knockdown cells and the cell expressing SGOL1-P12.4.24. In a lung cancer cell line transfected with SGOL1-B, considerable amount of centrosome amplification was noted. Several studies have demonstrated a relationship between exposure to carcinogens implicated in lung cancer and the development of centrosome abnormalities in vitro. SGOL1 is required for the protection of centromeric cohesion from prophase to the metaphase-anaphase transition until all the kinetochores have been properly captured by the spindle microtubules. In SGOL1-B1 overexpressed cells, the weakness of centromere protection induces accurate chromosome segregation on the metaphase plate, leading to mitotic delay. This result is consistent with the observation that cells expressing SGOL1-B showed a high frequency of mitotic cells with premature centromere separation that were delayed at the G2/M transition. Cells with SGOL1-B overexpression, which showed a cancer tissue-specific expression in primary lung cancer, induced aberrant mitosis, which accelerated the acquisition of further malignant phenotypes. On the other hand, in terms of concurrent centrosome amplification associated with SGOL1-B overexpression as described above, centrosome proteins like PLK4 and Tpx2 are also known to be involved with generation of aberrant mitosis, the same phenotype shown here. Actually, a high frequency of mitotic errors are notable in lung cancer cells spontaneously occurring in mice heterozygous for PLK4 and Tpx2. Our study showing that the overexpression of SGOL1-B is observed in lung cancer provides a new and important link between aberrant mitosis and lung carcinogenesis.

Figure 4 | Difference in taxane responses of WT EGFR NSCLC cell lines according to their SGOL1-B expression level. (a) SGOL1-B mRNA expression levels determined using quantitative real-time RT-PCR in three NSCLC cell lines with WT EGFR and a cell line with EGFR mutation. The data shown are the mean of at least three independent experiments. (b) Responses of PC-3, A549, H1299 and ACC-LC-176 cells to docetaxel and paclitaxel treatment as evaluated using a WST-8 colorimetric assay. (c) Representative images of time-lapse sequences illustrating the two types of death after exposure to docetaxel. Scale bar = 10 μm. The number at the upper right of each panel indicates the time in minutes. (d) Percentages of PC-3, A549, H1299 and ACC-LC-176 cells exhibiting various cell fates in response to 1,000 nM of docetaxel.
microtubule dynamics. It is tempting to speculate that the assessment of SGOL1-B expression might be a predictive marker for taxane-based chemotherapy. Until now, several markers are proposed as predictors of responses to taxane therapy. Especially, high levels of βIII-tubulin expression in NSCLC are associated with low response rates and poorer survival in patients treated with chemotherapies based on anti-mitotic agents. Our data indicate that a taxane-resistant lung cancer cell line expresses higher mRNA levels of a specific SGOL1 splice variant, SGOL1-B. The determination of the SGOL1-B mRNA level may be useful for selecting subjects who are likely to benefit from chemotherapy based on taxanes.

The molecular pathways resulting in taxane-induced cell death without mitosis entry (“death in interphase”) or death in response to aberrant mitosis (“death in mitosis”) remain unclear. In our study, lung cancer cells with a high expression level of SGOL1-B were more resistant to mitotic arrest induced by taxane than other cell lines with a low expression level of SGOL1-B. Although mitotic arrest is a hallmark cellular response to taxane, previous studies have shown that the antitumor efficacy of paclitaxel is dependent on its ability to induce apoptosis, not mitotic arrest. Another study with NSCLC A549 cells also found that low concentrations of paclitaxel are sufficient to induce cell death without an apparent G2-M block. These reports strongly support our result that A549, which had a low expression level of SGOL1-B, was taxane-sensitive. The expression level of SGOL1-B may alter cellular fate profiles.

We do not know exactly what produced the multitude of genetic changes in lung cancer cases with SGOL1-B overexpression. Our analysis may provide an insight that abnormal mitosis in response to an elevated SGOL1-B level posits the cancer cells as having a high frequency of focal copy number amplifications. NSCLC cells with a high expression level of SGOL1-B that were exposed to taxane underwent mitotic arrest. The mechanism of taxane-resistance might be associated with abnormal mitosis induced by SGOL1-B and mitotic arrest induced by taxane. These findings underlie the importance of determining the SGOL1-B expression status, which could be used in addition to the EGFR status in the selection of candidates for chemotherapy.

Figure 5 | Expression level of SGOL1-B defines the response to docetaxel. (a) Responses of empty vector (mock)- and SGOL1-B1-transfected A549 NSCLC cells to docetaxel and paclitaxel as evaluated using a WST-8 colorimetric assay. The data shown are the mean of at least three independent experiments. (b) Representative images of “death in mitosis” in A549 cells overexpressing SGOL1-B1 detected using time-lapse microscopy. Scale bar = 10 μm. An attached graph shows percentages of mock- and SGOL1-B1 expression vector-transfected A549 cells exhibiting “death in mitosis” in response to 1,000 nM of docetaxel. (c) Western blot analysis of expression of SGOL1-B in ACC-LC-176 NSCLC cells after shRNA knockdown for SGOL1-B was inside the graph. Cropped images are shown and the original whole gels are available in Supplementary Figure S3 online. (d) Responses of mock vector- and SGOL1-B shRNA expression vector-transfected ACC-LC-176 cells to docetaxel and paclitaxel as evaluated using a WST-8 colorimetric assay. The data shown are the mean of at least three independent experiments. (e) Representative images of “death in interphase” of SGOL1-B-knockdown ACC-LC-176 cells detected using time-lapse microscopy. Scale bar = 10 μm. An attached graph shows percentages of mock- and SGOL1-B shRNA expression vector-transfected ACC-LC-176 cells exhibiting “death in interphase” in response to 1,000 nM of docetaxel.
taxane-based chemotherapy. We are even tempted to expect that the manipulative downregulation of SGOL1-B may increase the sensitivity of the cancer cells to taxane.

Methods

All experiments were performed in accordance with relevant guidelines and regulations. All the study protocols were approved by the Institutional Review Board of Hamamatsu University School of Medicine (reference number 23–91).

Tissue samples and nucleic acid extraction. Tissues from patients with primary NSCLC were surgically resected at the Hamamatsu University Hospital (Japan), Shimada Municipal Hospital (Japan), and Seto Mikatahara General Hospital (Japan). Written informed consent was obtained from all subjects. Total RNA and genomic DNA were extracted from the tumors and normal tissues using the commercially available ISOGEN kit (Nippongene, Tokyo, Japan) and the DNeasy Tissue kit (QIAGEN, Valencia, CA, USA), according to the manufacturers’ instructions. The tumor tissues were examined for somatic mutations in mutation cluster regions (hot spots) of the EGFR gene. The primers used for PCR and DNA sequencing have been described previously21. The study design was approved by the Institutional Review Boards of the relevant hospitals.

Quantitative real-time RT-PCR and plasmid construction. The structure and nomenclature of the transcripts of SGOL1 is shown in Figure 1a. Isoform SGOL1-B does not contain part of exon 6. We measured SGOL1-B, including both SGOL1-B1 and SGOL1-B2, using common primers. For the in vitro experiments, we used a construct of SGOL1-B containing exon 8.

Quantitative real-time RT-PCR was performed as described in our previous report8. The primer sequences used for the first RT-PCR for SGOL1 (Figure 1b) were as follows: forward, 5'-GACCCCAATGCTGGACG-3', reverse, 5'-GAAATGTCTCCTTGGCTCTG-3'. For the amplification of each SGOL1 variant, the following primer sequences were used: the common forward primer for SGOL1-A, -B, and -C was 5'-TCTCAGAAATATTATTGTAAGG-3', and the reverse primers for SGOL1-A, -B, and -C were 5'-CAAAATCAATCCCTCGGTGTC-3', 5'-GTTGTTGTGTAATCTGAAATAAC-3', and 5'-GTTTAGCAGTGGTCTGCTTATG-3', respectively. The Glyceroldehyde-3-phosphate dehydrogenase (GAPDH) transcript was amplified as an internal control, as described previously22. To express SGOL1-B in mammalian cells, three MYC tag sequences were fused to the 5'-side of SGOL1-B1 using PCR amplification, and the product was inserted into a pIRISpuro2 expression vector (Clontech, Palo Alto, CA, USA). A pSilencer shRNA containing the inserts was transfected into H1299 cells, and the SGOL1 and SGOL1-B sequences were used for the RNA interference (RNAi) procedure, as described previously23. The SGOL1-B shRNA expression vector was constructed by inserting shRNA sequences targeting SGOL1-B (target sequence: 5'-GATTACCCTACACCACCTGTA-3') into pSilencer 2.1-U6 puro (Applied Biosystems, Tokyo, Japan).

Fluorescence in situ hybridization (FISH) analysis. FISH analysis was performed on FFPE tumor samples and cell lines according to the manufacturers’ instructions with minor modifications, as described previously24,25. Spectrum Orange-labeled BAC clones, RP11-106B16 (9p21.3, EGFR), RP11-245 + 5p15-355N16 (3q26.3, PKI3CA), RP11-275S4 (3q26.3, SOX2), RP11-51M22 (7q31.1, MET), and RP5-109E11 (7q12, EGFR) (Advanced GenoTechs Co., Tsukuba, Japan), were used as locus-specific FISH probes. Spectrum Green-labeled control probes for the near centromere locus on chromosome 3 (RP11-91A5), 7 (RP11-90C3), and 8 (RP11-12L15) (Advanced GenoTechs Co.) were also used to enumerate the copies of chromosome 3, 7, and 8 in the FISH experiments. 4',6-Diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA) was used for nuclear staining. At least 50 tumor cell nuclei were counted per case. Copy number amplification was defined by a BAC signal/CEP ratio greater than or equal to 2.0 or the presence of a tight gene cluster.

Cell culture and transfection. The human NSCLC cell lines A549 (adenocarcinoma), PC-3 (adenocarcinoma), H1299 (large cell carcinoma) and ACC-LLC-176 (squamous cell carcinoma) were cultured at 37°C in RPMI medium (Invitrogen, Carlsbad, CA, USA) containing 5% or 10% fetal bovine serum (Nichirei, Tokyo, Japan) under 5% CO2. The A549 and H1299 cell lines were gifts from Dr. Niki (Jichi Medical University), and the ACC-LLC-176 cell line was a gift from Dr. Takahashi (Nagoya University). Transfection was performed using a Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol.

Antibodies. Rabbit polyclonal anti-shugoshin (ab21635; Abcam, Cambridge, MA, USA) and anti-MYC tag (9E10; Sigma, St. Louis, MO, USA) antibodies and mouse monoclonal anti-β-tubulin (GTU88; Sigma), anti-β-tubulin (ab80823; Abcam) antibodies were used for western blotting and immunofluorescence staining as primary antibodies. A human autoantibody against the centromere (ImmunoVision, Springfield, AR, USA) was used for the immunofluorescent staining of the kinetochores. HRP-conjugated donkey polyclonal anti-rabbit antibody or anti-mouse IgG antibody (GE Healthcare, Piscataway, NJ, USA) and Alexa Fluor 488/546/633-labeled goat polyclonal anti-rabbit, anti-mouse or anti-human IgG antibodies (Invitrogen) were used as secondary antibodies.
and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 26, 468–473 (2008).
10. Weaver, B. A. & Cleveland, D. W. Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7–12 (2005).
11. Weiss, J. et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2, 62ra93 (2010).
12. Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 41, 1238–1242 (2009).
13. Okudela, K. et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int. 57, 664–671 (2007).
14. Cappuzzo, F. et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 27, 1667–1674 (2009).
15. Tsao, M. S. et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 353, 133–144 (2005).
16. Jordan, M. A. & Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 10, 123–130 (1998).
17. Gascoigne, K. E. & Taylor, S. S. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitic drugs. Cancer Cell 14, 111–122 (2008).
18. Kitamura, S. et al. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Ipn J Cancer Res. 90, 75–80 (1999).
19. Chang, T. H. & Szabo, E. Induction of differentiation and apoptosis by lipids of peroxisome proliferator-activated receptor γ in non-small-cell lung cancer. Cancer Res. 60, 1129–1138 (2000).
20. Passeron, T. et al. Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest. 119, 954–963 (2009).
21. Jiang, S. S. et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 16, 4363–4373 (2010).
22. Watanabe, Y., Ikemura, T. & Sugimura, H. Amplicons on human chromosome 11q are located in the early/late-switch regions of replication timing. Genomics 84, 796–805 (2004).
23. Dufi, P. H. & Benezra, R. The cancer biology of whole-chromosome instability. Oncogene 32, 1–10 (2013).
24. Dai, J., Katenneva, V. & Higgins, J. M. Studies of haspin-depleted cells reveal that spindle-pole integrity in mitosis requires chromosome cohesion. J Cell Sci. 122, 4168–4176 (2009).
25. Shimamura, K. et al. Induction of centrosome amplification and chromosome instability in p53-deficient lung cancer cells exposed to benzo[a]pyrene diol epoxide (B[a]PDE). J Pathol. 216, 365–374 (2008).
26. Xie, H. et al. Neoplastic transformation of human bronchial cells by lead chromate particles. Am J Respir Cell Mol Biol. 37, 544–552 (2007).
27. Watanabe, Y. Shugoshin: guardian spirit at the centromere. Curr Opin Cell Biol. 17, 590–595 (2005).
28. Ko, M. A. et al. Pkl4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet. 37, 883–888 (2005).
29. Aguirre-Portoles, C. et al. Tpv2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 72, 1518–1528 (2012).
30. Zelnak, A. B. Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. Methods Mol Med. 137, 209–234 (2007).
31. Yerushalmi, R., Woods, R., Ravdin, P. M., Hayes, M. M. & Gelmon, K. A. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 11, 174–183 (2010).
32. Honma, K. et al. RPN2 gene confers doxoralexa resistance in breast cancer. Nat Med. 14, 939–948 (2008).
33. Gan, P. P., Pasquier, E. & Kavallaris, M. Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res. 67, 9356–9363 (2007).
34. Seve, P. et al. Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther. 4, 2001–2007 (2005).
35. Villmar, A. C., Santoni-Rugiu, E. & Sorensen, J. B. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res. 17, 5205–5214 (2011).
36. Janssen, A. & Medema, R. H. Mitosis as an anti-cancer target. Oncogene 30, 2799–2809 (2011).
37. Milross, C. G. et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 88, 1308–1314 (1996).
38. Torres, K. & Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58, 3620–3626 (1998).
39. Davies, H. et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65, 7591–7595 (2005).
40. Sugimura, H. Detection of chromosome changes in pathology archives: an application of microwave-assisted fluorescence in situ hybridization to human carcinogenesis studies. Carcinogenesis 29, 681–687 (2008).
41. Sugimura, H. et al. Fluorescence in situ hybridization analysis with a tissue microarray: ‘FISH and chips’ analysis of pathology archives. Pathol Int. 60, 543–550 (2010).
42. Shimamura, K. et al. Reduced expression of MUTYH with suppressive activity against mutations caused by 8-hydroxyquinone is a novel predictor of a poor prognosis in human gastric cancer. J Pathol. 225, 414–423 (2011).

Acknowledgments
We are grateful to Dr. Niki (Jichi Medical University, Shimotuke, Japan) for providing us with a lung cancer cell line. We also acknowledge Mrs. K. Nagura, Mr. T. Kamo and Mr. S. Kageyama (Hamamatsu University School of Medicine) for their technical assistance. We appreciate Dr. Shuji Ogin (Brigham and Women’s Hospital) and Dr. Mari Iida and Dr. Roger Wiseman (University of Wisconsin) for a critical reading of the manuscript. This work was supported by grants from the Ministry of Health, Labour and Welfare (19–19, 10103838), the Japan Society for the Promotion of Science (22590356, 23790396), Ministry of Education, Culture, Sports, Science and Technology (S-001), National Cancer Research and Development Fund, and the Smoking Research Foundation.

Additional information
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0

Supplementary information
This article is accompanied by Supplementary information at the website of Scientific Reports. This information is available as a separate PDF file and as HTML pages on the site. It includes additional data, methods, and figures to support the main text of the article. The Supplementary information is an important part of the manuscript and should be included whenever possible. It can help to provide more detailed information about the research and allow readers to reproduce the experiments. The Supplementary information should be cited in the main text and can be accessed via links included in the manuscript.